Logo image of CGEN

COMPUGEN LTD (CGEN) Stock Fundamental Analysis

NASDAQ:CGEN - Nasdaq - IL0010852080 - Common Stock - Currency: USD

2.06  -0.04 (-1.9%)

Fundamental Rating

4

CGEN gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. CGEN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CGEN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

CGEN had positive earnings in the past year.
In the past year CGEN had a positive cash flow from operations.
CGEN had negative earnings in each of the past 5 years.
CGEN had a negative operating cash flow in each of the past 5 years.
CGEN Yearly Net Income VS EBIT VS OCF VS FCFCGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

With an excellent Return On Assets value of -8.65%, CGEN belongs to the best of the industry, outperforming 88.06% of the companies in the same industry.
CGEN has a Return On Equity of -16.33%. This is amongst the best in the industry. CGEN outperforms 88.24% of its industry peers.
Industry RankSector Rank
ROA -8.65%
ROE -16.33%
ROIC N/A
ROA(3y)-25.7%
ROA(5y)-29.88%
ROE(3y)-34.67%
ROE(5y)-40.04%
ROIC(3y)N/A
ROIC(5y)N/A
CGEN Yearly ROA, ROE, ROICCGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

CGEN has a Gross Margin of 73.63%. This is amongst the best in the industry. CGEN outperforms 84.85% of its industry peers.
CGEN's Gross Margin has been stable in the last couple of years.
CGEN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 73.63%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.04%
GM growth 5Y-0.04%
CGEN Yearly Profit, Operating, Gross MarginsCGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K -4K

More info and screens

6

2. Health

2.1 Basic Checks

CGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CGEN has been increased compared to 1 year ago.
CGEN has more shares outstanding than it did 5 years ago.
CGEN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CGEN Yearly Shares OutstandingCGEN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
CGEN Yearly Total Debt VS Total AssetsCGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

CGEN has an Altman-Z score of -2.88. This is a bad value and indicates that CGEN is not financially healthy and even has some risk of bankruptcy.
CGEN has a Altman-Z score (-2.88) which is comparable to the rest of the industry.
CGEN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z -2.88
ROIC/WACCN/A
WACC9.11%
CGEN Yearly LT Debt VS Equity VS FCFCGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M

2.3 Liquidity

A Current Ratio of 4.12 indicates that CGEN has no problem at all paying its short term obligations.
The Current ratio of CGEN (4.12) is comparable to the rest of the industry.
A Quick Ratio of 4.12 indicates that CGEN has no problem at all paying its short term obligations.
CGEN's Quick ratio of 4.12 is in line compared to the rest of the industry. CGEN outperforms 48.66% of its industry peers.
Industry RankSector Rank
Current Ratio 4.12
Quick Ratio 4.12
CGEN Yearly Current Assets VS Current LiabilitesCGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

6

3. Growth

3.1 Past

CGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 105.41%, which is quite impressive.
Looking at the last year, CGEN shows a very strong growth in Revenue. The Revenue has grown by 698.03%.
The Revenue has been growing by 13.45% on average over the past years. This is quite good.
EPS 1Y (TTM)105.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%109.09%
Revenue 1Y (TTM)698.03%
Revenue growth 3Y155.76%
Revenue growth 5Y13.45%
Sales Q2Q%N/A

3.2 Future

CGEN is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -4.59% yearly.
Based on estimates for the next years, CGEN will show a quite strong growth in Revenue. The Revenue will grow by 16.63% on average per year.
EPS Next Y23.5%
EPS Next 2Y20.15%
EPS Next 3Y13.82%
EPS Next 5Y-4.59%
Revenue Next Year95.67%
Revenue Next 2Y22.17%
Revenue Next 3Y20.04%
Revenue Next 5Y16.63%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CGEN Yearly Revenue VS EstimatesCGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 20M 40M 60M 80M 100M
CGEN Yearly EPS VS EstimatesCGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 -0.2 -0.4 -0.6

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 103.00 indicates a quite expensive valuation of CGEN.
Compared to the rest of the industry, the Price/Earnings ratio of CGEN indicates a rather cheap valuation: CGEN is cheaper than 92.87% of the companies listed in the same industry.
CGEN is valuated expensively when we compare the Price/Earnings ratio to 29.62, which is the current average of the S&P500 Index.
The Forward Price/Earnings Ratio is negative for CGEN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 103
Fwd PE N/A
CGEN Price Earnings VS Forward Price EarningsCGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Compared to the rest of the industry, the Price/Free Cash Flow ratio of CGEN indicates a rather cheap valuation: CGEN is cheaper than 98.40% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 8.28
EV/EBITDA N/A
CGEN Per share dataCGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
CGEN's earnings are expected to grow with 13.82% in the coming years. This may justify a more expensive valuation.
PEG (NY)4.38
PEG (5Y)N/A
EPS Next 2Y20.15%
EPS Next 3Y13.82%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CGEN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COMPUGEN LTD

NASDAQ:CGEN (2/24/2025, 3:17:35 PM)

2.06

-0.04 (-1.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)03-04 2025-03-04/amc
Inst Owners14.98%
Inst Owner Change-82.7%
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap184.45M
Analysts88
Price Target4.08 (98.06%)
Short Float %1.67%
Short Ratio1.8
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-92.46%
Min EPS beat(2)-256.51%
Max EPS beat(2)71.58%
EPS beat(4)1
Avg EPS beat(4)-63.45%
Min EPS beat(4)-256.51%
Max EPS beat(4)71.58%
EPS beat(8)4
Avg EPS beat(8)-20.87%
EPS beat(12)8
Avg EPS beat(12)-5.93%
EPS beat(16)11
Avg EPS beat(16)-3.13%
Revenue beat(2)1
Avg Revenue beat(2)52.02%
Min Revenue beat(2)-59.62%
Max Revenue beat(2)163.65%
Revenue beat(4)2
Avg Revenue beat(4)17.01%
Min Revenue beat(4)-100%
Max Revenue beat(4)163.65%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-27.27%
PT rev (3m)-20%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-3.12%
EPS NY rev (3m)-333.48%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-14.66%
Revenue NY rev (3m)13.08%
Valuation
Industry RankSector Rank
PE 103
Fwd PE N/A
P/S 4.32
P/FCF 8.28
P/OCF 8.22
P/B 3.16
P/tB 3.16
EV/EBITDA N/A
EPS(TTM)0.02
EY0.97%
EPS(NY)-0.12
Fwd EYN/A
FCF(TTM)0.25
FCFY12.08%
OCF(TTM)0.25
OCFY12.16%
SpS0.48
BVpS0.65
TBVpS0.65
PEG (NY)4.38
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.65%
ROE -16.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 73.63%
FCFM 52.17%
ROA(3y)-25.7%
ROA(5y)-29.88%
ROE(3y)-34.67%
ROE(5y)-40.04%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.04%
GM growth 5Y-0.04%
F-Score5
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 31.43%
Cap/Sales 0.35%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.12
Quick Ratio 4.12
Altman-Z -2.88
F-Score5
WACC9.11%
ROIC/WACCN/A
Cap/Depr(3y)67.09%
Cap/Depr(5y)48.21%
Cap/Sales(3y)3.96%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)105.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%109.09%
EPS Next Y23.5%
EPS Next 2Y20.15%
EPS Next 3Y13.82%
EPS Next 5Y-4.59%
Revenue 1Y (TTM)698.03%
Revenue growth 3Y155.76%
Revenue growth 5Y13.45%
Sales Q2Q%N/A
Revenue Next Year95.67%
Revenue Next 2Y22.17%
Revenue Next 3Y20.04%
Revenue Next 5Y16.63%
EBIT growth 1Y87.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y173.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y175.29%
OCF growth 3YN/A
OCF growth 5YN/A